The word incretin turns up in every description of a modern metabolic research peptide, usually without explanation. It names a specific observation about how the body handles glucose, and that observation is the reason this whole family of compounds exists.

The observation the word names

Give the same amount of glucose two ways, by mouth and directly into a vein, and the insulin response is larger when it arrives through the gut. The gap between those two responses is the incretin effect, and it was quantified by comparing the two routes at matched glucose levels. (Reference: Nauck et al., 1986)

Something released by the gut is therefore contributing to the response. Incretins are the hormones that do it.

The two that research concentrates on

  • GIP, glucose-dependent insulinotropic polypeptide, released by enteroendocrine cells concentrated in the upper small intestine.
  • GLP-1, glucagon-like peptide-1, released by cells found further along the gut and the more heavily studied of the pair.

Each acts through its own receptor, and the two receptors belong to the same structural family as the glucagon receptor. (Reference: Mayo et al., 2003) Our note on GLP-1 and GIP compares the two directly.

Why the ligands are long peptides

The incretin receptors sit in the class of G protein-coupled receptors that includes the glucagon and secretin receptors. (Reference: Mayo et al., 2003) Receptors in this class carry a large extracellular domain in front of the membrane-spanning part, and the ligand binds across both: one end of the peptide is held by that outer domain while the other reaches down into the transmembrane core.

Two consequences follow. The ligand has to be long enough to span both sites, which is why these hormones and the compounds built from them run to thirty or forty residues instead of a handful. And a molecule that binds across a long interface gives a chemist many positions to modify, which is what makes substitution at the cleavage site and acylation at a chosen residue practical in the first place.

Where each one comes from

The two hormones are released by different cells in different parts of the gut, which is why nutrients arriving at different points do not produce identical signals. GIP comes from cells concentrated in the upper small intestine. GLP-1 comes from cells that are more common further along. The distribution matters to anyone reading the literature, because a study that manipulates where nutrients are absorbed is manipulating the balance between the two. (Reference: Baggio & Drucker, 2007)

Both are cut by the same enzyme, and quickly

This is the fact that explains most of what synthetic peptides in this family look like. An enzyme called dipeptidyl peptidase-4 removes the first two residues from the end of both hormones, and that clipped form no longer activates the receptor the way the intact one does. The enzyme is widespread, so the native hormones are short-lived. (Reference: Mentlein, 1999)

A molecule meant to be studied over hours instead of minutes has to survive that. Two design moves follow, and both are visible in the compounds themselves.

  • Change the residues the enzyme reads. Substituting near the cleavage site removes the enzyme's grip.
  • Attach a fatty acid. Acylation lets the molecule associate reversibly with serum albumin, and albumin-bound peptides are cleared more slowly. (Reference: Hijazi, 2021)

Both changes also make the molecule bigger and more hydrophobic, which is why these compounds behave differently from an ordinary short peptide on a reversed-phase column.

Why the receptors became targets

Once two receptors are known to sit on the same pathway, the obvious laboratory question is what changes when a single molecule engages one, the other, or both. That question produced the current generation of compounds: agonists selective for GLP-1, dual agonists that engage GIP as well, and triple agonists that add the glucagon receptor.

Engaging two receptors is not the same as engaging them equally. Receptor pharmacology work has described at least one dual agonist as unbalanced across its two targets, so the count of receptors in a description says less than it appears to. (Reference: Willard et al., 2020) The general vocabulary is covered in our note on agonists and antagonists.

A note on the numbers after the name

GLP-1 appears in the literature with a numeric range attached, because the active hormone is a fragment cut from a larger precursor and more than one fragment exists. One of the circulating forms also ends in an amide instead of a free acid. Those numbers and that ending are part of the identity of the molecule, and they change its mass, so a specification that quotes them is quoting something a measurement can confirm. (Reference: Baggio & Drucker, 2007)

Glucose dependence

The name GIP carries a detail worth reading: glucose-dependent. The insulin-releasing activity of these hormones is tied to glucose being present, so the signal is conditional on the state the system is already in. This is part of why the incretin axis is studied as a regulatory mechanism and not as a simple switch. (Reference: Baggio & Drucker, 2007)

What this means for a vial

Knowing the biology explains why these compounds are designed the way they are. It says nothing about the material in front of you. A long, acylated peptide is harder to synthesise cleanly than a short one, so the purity figure and the identity measurement on its certificate of analysis carry more weight here, and a batch can be checked against its paperwork by batch number.

Scope

Everything above is background biology and laboratory context. All products sold by Codex Research are strictly for laboratory research and development. They are not for human or animal consumption and are not intended to diagnose, treat, cure, or prevent any disease.

These compounds in the catalog

Frequently asked questions

What are incretins?

Hormones released by the gut that contribute to the insulin response when nutrients arrive that way. The same glucose load produces a larger response by mouth than directly into a vein, and the gap between the two is the incretin effect.

Which are the two main incretins?

GIP, glucose-dependent insulinotropic polypeptide, and GLP-1, glucagon-like peptide-1. Each acts through its own receptor, and both receptors belong to the same structural family as the glucagon receptor.

Why are native incretins short-lived?

An enzyme called dipeptidyl peptidase-4 removes the first two residues from both hormones, and the clipped form no longer activates the receptor the way the intact one does. The enzyme is widespread, so the native hormones do not last long.

Why do synthetic incretin peptides carry a fatty acid?

Acylation lets the molecule associate reversibly with serum albumin, and albumin-bound peptides are cleared more slowly. It also makes the molecule more hydrophobic, which changes how it behaves on a reversed-phase column.

What does glucose-dependent mean in the name GIP?

That the insulin-releasing activity is tied to glucose being present, so the signal depends on the state the system is already in. It is studied as a regulatory mechanism rather than a simple switch.

Does engaging two incretin receptors mean twice the effect?

No. Receptor pharmacology work has described at least one dual agonist as unbalanced across its two targets, so the number of receptors named in a description says little about how the activity is distributed between them.

References

Related articles